Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NovaBay Pharma ( (NBY) ) has provided an announcement.
On March 23, 2026, NovaBay Pharmaceuticals announced it will change its corporate name to Stablecoin Development Corporation and expects to begin trading on NYSE American under the new ticker SDEV on April 3, 2026, marking a formal pivot into the stablecoin and digital asset infrastructure sector. The company detailed progress on its January 2026 $134 million private placement and strategic realignment, disclosing holdings of about 2.06 billion SKY tokens—roughly 8.78% of the total supply—earned 26.6 million SKY in staking rewards by March 16, 2026, and adopted staggered warrant exercises and trading covenants designed to support orderly market dynamics while pursuing a long-duration, on-chain holding company strategy centered on the Sky protocol ecosystem.
The January 2026 financing brought in prominent digital asset investors, including Tether affiliates, and furnished SDEV with cash, stablecoins, and 943.6 million SKY tokens, supplemented by 1.09 billion additional SKY bought on the open market at an average price of $0.065 per token. By concentrating its capital allocation and risk framework around SKY and the Sky protocol’s USDS stablecoin platform, SDEV is seeking to position itself as a long-term institutional participant in the expanding stablecoin economy, highlighting its focus on governance-driven staking income, protocol-level economics, and mechanisms aimed at aligning investors with a gradual, rather than speculative, liquidity profile.
The most recent analyst rating on (NBY) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
Spark’s Take on NBY Stock
According to Spark, TipRanks’ AI Analyst, NBY is a Neutral.
The score is driven primarily by very weak financial performance (revenue collapse, persistent losses, ongoing cash burn, and negative equity). Technicals also reflect bearish momentum with the stock trading below major moving averages. Corporate actions add funding flexibility but introduce meaningful dilution and strategy-risk concerns, while valuation metrics provide limited support due to negative earnings.
To see Spark’s full report on NBY stock, click here.
More about NovaBay Pharma
NovaBay Pharmaceuticals, soon to be renamed Stablecoin Development Corporation, is repositioning from its legacy pharma roots into a digital-asset-focused, on-chain holding company. The business aims to become a public-market gateway to stablecoin-related cash flows, concentrating on the Sky protocol ecosystem and its governance token SKY within the broader stablecoin and decentralized finance markets.
Average Trading Volume: 508,748
Technical Sentiment Signal: Strong Sell
Current Market Cap: $30.89M
Learn more about NBY stock on TipRanks’ Stock Analysis page.